The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer

Axicabtagene ciloleucel as first-line therapy in high-risk large B

Cetuximab, fluorouracil and cisplatin with or without docetaxel

A randomized phase III study of fractionated docetaxel

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine

Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin

Comprehensive review on how platinum- and taxane-based

Expert Insight on Optimal Treatment Selection for Patients With

Paclitaxel plus platinum-based chemotherapy versus conventional

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

Randomized phase III trial of dose-dense Methotrexate, Vinblastine

Randomized Phase III Trial of Concurrent Accelerated Radiation